Fibrosis Improvement Achieved in 81.8% of Patients

DND Pharmatech, a company specializing in new drug development research, announced on June 18 that the results of a 48-week phase 2 biopsy of DD01 (Zavopiglutide), its investigational drug for the treatment of MASH (Metabolic dysfunction-associated steatohepatitis), showed significant improvement in liver fibrosis compared to placebo. The analysis was conducted using “qFibrosis,” an AI-based digital pathology platform from Histolndex, a Singapore-based digital pathology company.


DND Pharmatech company logo image. DND Pharmatech

DND Pharmatech company logo image. DND Pharmatech

View original image

Histolndex’s AI analysis evaluates fibrotic changes by quantifying collagen structure and density. This served as an additional analysis to complement the objectivity of clinical data alongside the traditional assessments by pathologists.


This analysis was conducted on 27 patients (16 in the placebo group, 11 in the Zavopiglutide group) who adhered to the clinical trial protocol and had a baseline fibrosis stage of F1 or higher.


According to the fat-adjusted analysis, the proportion of patients who achieved at least a one-stage improvement in fibrosis was 81.8% in the Zavopiglutide group, which was 63 percentage points higher than the 18.8% observed in the placebo group.

In the quantitative fibrosis assessment, the fibrosis index in the Zavopiglutide group decreased by 41.0% compared to baseline. In contrast, the placebo group saw an increase of 9.5%, resulting in a placebo-adjusted decrease of 50.5%.


Previously, DND Pharmatech unveiled the results of the 48-week phase 2 biopsy based on pathologist assessment at the European Association for the Study of the Liver (EASL 2026). At that time, the Zavopiglutide group demonstrated statistically significant improvement over placebo in key histological endpoints, including MASH resolution without worsening of fibrosis, fibrosis improvement without worsening of MASH, and a composite endpoint of both MASH resolution and fibrosis improvement.


DND Pharmatech explained that the 50.5% placebo-adjusted reduction in fibrosis index observed with Histolndex’s AI-based tissue analysis is competitive, even when compared to currently approved MASH treatments and late-stage investigational candidates.



Zavopiglutide is designed to allow dose escalation over two weeks to reach the maximum dose, and in clinical trials, the discontinuation rate due to gastrointestinal side effects was 8%.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing